Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth Lederman

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Plos One|January 20, 2018
Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragmentsRyan S Noyce, Seth Lederman, David H Evans
Vaccine|June 1, 2020
Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industryJosé Esparza, Seth Lederman, Andreas Nitsche, et al.
Journal of Clinical Immunology|April 29, 2026
First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy AdultsSeth Lederman, Bruce L Daugherty, Nancy Herje, et al.
Journal of Biopharmaceutical Statistics|June 6, 2022
Randomization tests in clinical trials with multiple imputation for handling missing dataAnastasia Ivanova, Seth Lederman, Philip B Stark, et al.
The Journal of Rheumatology|September 3, 2011
Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled studyHarvey Moldofsky, Herbert W Harris, W Tad Archambault, et al.
Arthritis Care & Research|May 11, 2023
Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled TrialSeth Lederman, Lesley M Arnold, Ben Vaughn, et al.
Clinical Pharmacology in Drug Development|April 8, 2026
Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label TrialGregory M Sullivan, Bernd Meibohm, Errol Gould, et al.
Clinical Pharmacology in Drug Development|February 27, 2026
Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy VolunteersBruce L Daugherty, Bernd Meibohm, Gregory M Sullivan, et al.
Pain|December 19, 2023
Chronic overlapping pain conditions increase the risk of long COVID features, regardless of acute COVID statusRachel S Bergmans, Daniel J Clauw, Candace Flint, et al.
Pain Medicine (Malden, Mass.)|July 8, 2025
Pain Relief by Targeting Nonrestorative Sleep in Fibromyalgia: A Phase 3 Randomized Trial of Bedtime Sublingual CyclobenzaprineSeth Lederman, Lesley M Arnold, Ben Vaughn, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Plos One|January 20, 2018
Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragmentsRyan S Noyce, Seth Lederman, David H Evans
Vaccine|June 1, 2020
Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industryJosé Esparza, Seth Lederman, Andreas Nitsche, et al.
Journal of Clinical Immunology|April 29, 2026
First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy AdultsSeth Lederman, Bruce L Daugherty, Nancy Herje, et al.
Journal of Biopharmaceutical Statistics|June 6, 2022
Randomization tests in clinical trials with multiple imputation for handling missing dataAnastasia Ivanova, Seth Lederman, Philip B Stark, et al.
The Journal of Rheumatology|September 3, 2011
Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled studyHarvey Moldofsky, Herbert W Harris, W Tad Archambault, et al.
Arthritis Care & Research|May 11, 2023
Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled TrialSeth Lederman, Lesley M Arnold, Ben Vaughn, et al.
Clinical Pharmacology in Drug Development|April 8, 2026
Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label TrialGregory M Sullivan, Bernd Meibohm, Errol Gould, et al.
Clinical Pharmacology in Drug Development|February 27, 2026
Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy VolunteersBruce L Daugherty, Bernd Meibohm, Gregory M Sullivan, et al.
Pain|December 19, 2023
Chronic overlapping pain conditions increase the risk of long COVID features, regardless of acute COVID statusRachel S Bergmans, Daniel J Clauw, Candace Flint, et al.
Pain Medicine (Malden, Mass.)|July 8, 2025
Pain Relief by Targeting Nonrestorative Sleep in Fibromyalgia: A Phase 3 Randomized Trial of Bedtime Sublingual CyclobenzaprineSeth Lederman, Lesley M Arnold, Ben Vaughn, et al.
Pageof 3